It was found that Pue adjuvant remedy could reduce the serum expression of NLRP3 inflammasome in patients with CHD, and the serum level of NLRP3 inflammasome in PUE-treated rats was also markedly lower as against CHD rats, indicating that Pue reduced the release of inflammatory mediators and the degree of inflammatory response by regulating the NLRP3 inflammasome signalling pathway. The gene discussed is NLRP3; the disease is coronary artery disorder.